Health Aug 11 Insurers view new Alzheimer’s drug as experimental, won’t cover treatment for some customers By Tom Murphy, Associated Press
Health Jul 17 A 2nd experimental Alzheimer’s drug shows promise, but comes with safety risks If U.S. regulators approve, the drug would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding. By Lauran Neergaard, Associated Press
Health Dec 30 Watch 5:57 FDA criticized for working too closely with biotech company to approve Alzheimer’s drug New findings from a congressional investigation into the Food and Drug Administration and the biotech company Biogen find the FDA broke its own protocols to approve a new Alzheimer’s drug last year. The report said the FDA worked too closely… By Geoff Bennett